US Patent or Application Number | Title | Owner/ Inventor | Comment |
---|
Application 20050288375,published 29 December 2005 | Method and composition for treating neurodegenerative disorders | Myriad Genetics,Salt Lake City, UT US | Claims ibogaine (and other compounds) used with an NSAID “for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, mild cognitive impairment." |
Application 20050222270 published 6 October 2005 and patent 5,958,919, issued 28 September 1999, and others | Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis | Washington University, St.Louis, MO US | Use of ibogaine to enhance safety in a technique to “ease problems such as addictions to illegal or pain-killing drugs, nicotine, or alcohol, compulsive or criminal behavioral problems, severe depression, obsessive-compulsive disorders, phobias, etc." |
Patent 6,416,793,issued 9 July 2002 | Formulations and use of controlled-release indolealkaloids | BioResponse,LLC, Boulder, CO, US | Ibogaine (and yohimbe) formulations with enhanced absorption by the body |
Patent 6,348,456,issued 19 February 2002, and Application 20030153552,published 14 August 2003 | Method of treating chemical dependency in mammals and a composition therefor | Mash; Deborah C. (University of Miami professor)and co-inventors | Claims noribogaine, a variant of ibogaine suitable for pharmaceuticals, and its use to treat addiction to “heroin, cocaine, alcohol, nicotine, amphetamine, methamphetamine, opium, methadone, hycodan, morphine and caffeine." |
Patent 6,211,360, issued 3 April 2001 | Ibogamine cogeners | Albany Medical College (Albany,NY, US) and the University of Vermont (US). | Ibogamine-derived compounds for treating drug addiction |
Patent 5,616,575, issued 1 April 1997 | Bioactive tricyclicibogaine analogs | University of Minnesota, US and University of Miami, US | Ibogamine-derived compounds for treating drug addiction |